Your browser doesn't support javascript.
loading
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Ponte-Sucre, Alicia; Gamarro, Francisco; Dujardin, Jean-Claude; Barrett, Michael P; López-Vélez, Rogelio; García-Hernández, Raquel; Pountain, Andrew W; Mwenechanya, Roy; Papadopoulou, Barbara.
Afiliação
  • Ponte-Sucre A; Department of Physiological Sciences, Laboratory of Molecular Physiology, Institute of Experimental Medicine, Luis Razetti School of Medicine, Universidad Central de Venezuela, Caracas, Venezuela.
  • Gamarro F; Department of Biochemistry and Molecular Pharmacology, Instituto de Parasitología y Biomedicina López-Neyra, Spanish National Research Council (IPBLN-CSIC), Granada, Spain.
  • Dujardin JC; Molecular Parasitology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Barrett MP; Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • López-Vélez R; Department of Infectious Diseases, National Referral Unit for Tropical Diseases, Ramón y Cajal University Hospital, Madrid, Spain.
  • García-Hernández R; Department of Biochemistry and Molecular Pharmacology, Instituto de Parasitología y Biomedicina López-Neyra, Spanish National Research Council (IPBLN-CSIC), Granada, Spain.
  • Pountain AW; Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Mwenechanya R; Department of Biomedical Sciences, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia.
  • Papadopoulou B; Research Center in Infectious Diseases, CHU de Quebec Research Center and Department of Microbiology-Infectious Disease and Immunology, University Laval, Quebec, Canada.
PLoS Negl Trop Dis ; 11(12): e0006052, 2017 Dec.
Article em En | MEDLINE | ID: mdl-29240765
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of "resistance" related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência a Medicamentos / Leishmaniose / Leishmania Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: PLoS Negl Trop Dis Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Venezuela País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência a Medicamentos / Leishmaniose / Leishmania Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: PLoS Negl Trop Dis Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Venezuela País de publicação: Estados Unidos